On September 17, Moderna, Inc. rose 3.52% in pre-market trading, trading at approximately $151.75/share, with turnover of $5.87 million, building on a 3.05% intraday gain earlier in the session to $148.14.

The rally is driven by a wave of institutional upgrades and heightened expectations surrounding Moderna's individualized mRNA cancer vaccine program. Multiple brokerages have recently raised their price targets on the stock after Moderna and Merck's co-developed personalized mRNA cancer vaccine reported positive Phase 3 clinical results in melanoma — the first-ever positive Phase 3 data for this class of therapy globally. Argus Research upgraded the stock to Buy with a $180 target, Barclays raised its target from $48 to $125, Berenberg lifted its target to $100 from $45, and UBS highlighted three near-term individualized neoantigen therapy data readouts as potential catalysts, maintaining a $150 target. The market is broadly reassessing the commercial value of mRNA technology in oncology. Additionally, Moderna recently completed a $2.6 billion convertible senior notes offering to fund its oncology business expansion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)